

Bölüm 8

OVERİN DİĞER KARSİNOMLARI

Tuğba GÜNLER¹

MEZONEFRİK BENZERİ ADENOKARSİNOM

Tanım

Mezonefrik benzeri adenokarsinomlar, overin mezonefrik farklılaşma gösteren malign epitelyal tümörleridir (1).

Epidemiyoloji ve Etyoloji

Bu tümörler oldukça nadir izlendiğinden epidemiyolojileri hakkında henüz yeterli veri mevcut değildir. Bu tümörlerin çoğunun postmenapozal kadınlarda görüldüğü bildirilmiştir (2). Etyolojileri bilinmemektedir (1).

Patogenez

Mezonefrik benzeri adenokarsinomların patogenezini tam belirlenememiştir. Bazı tümörlerin paraovaryal bölgedeki mezonefrik kalıntılardan; bazılarının ise ikincil mezonefrik transdiferansiyasyon sergileyen müllerian karsinomlarından kaynaklandığı düşünülmektedir. İkinci hipotez, mezonefrik benzeri adenokarsinomların endometriozis, kistadenomlar, adenofibroma, borderline tümörler ve

¹ Uzm. Dr. Tuğba GÜNLER, Sağlık Bilimleri Üniversitesi, Konya Şehir Hastanesi, Tıbbi Patoloji Bölümü, tubagurcan85@hotmail.com.

KAYNAKÇ A

1. Quick C M, Hoang LN, Malpica A. Mesonephric-like adenocarcinoma. In: Cheung AN, Ellenson LH, Gilks CB, Kim K-R KC, Lax SF, Longacre TA, et al., editors. *Female Genital Tumours, WHO Classification of Tumours*. 5 ed. France: International Agency for Research on Cancer (IARC); 2020. p. 77.
2. McFarland M, Quick CM, McCluggage WG. Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas. *Histopathology*. 2016 Jun;68(7):1013-20.
3. McCluggage WG, Vosmikova H, Laco J. Ovarian combined low-grade serous and mesonephric-like adenocarcinoma: further evidence for a Mullerian origin of mesonephric-like adenocarcinoma. *Int J Gynecol Pathol*. 2020 Jan;39(1):84-92.
4. Chapel DB, Joseph NM, Krausz T, et al. An ovarian adenocarcinoma with combined low grade serous and mesonephric morphologies suggests a Mullerian origin for some mesonephric carcinomas. *Int J Gynecol Pathol*. 2018 Sep;37(5):448-59.
5. Mirkovic J, McFarland M, Garcia E, et al. Targeted genomic profiling reveals recurrent KRAS mutations in mesonephric-like adenocarcinomas of the female genital tract.
6. Pars J, Cheng A, Leo JM, et al. A comparison of GATA3, TTF1, CD10, and calretinin in identifying mesonephric and mesonephric-like carcinomas of the gynecologic tract. *Am J Surg Pathol*. 2018 Dec;42(12):1 596-606.
7. Palacios J, Lee CH, Ramalingam P. Undifferentiated and dedifferentiated carcinomas of the ovary In: Cheung AN, Ellenson LH, Gilks CB, Kim K-R KC, Lax SF, Longacre TA, et al., editors. *Female Genital Tumours, WHO Classification of Tumours*. 5 ed. France: International Agency for Research on Cancer (IARC); 2020. p. 79.
8. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in turner type in low-stage versus high-stage ovarian carcinomas. *Int J Gynecol Pathol*. 2010 May;29(3):203-11Tafe LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. *Mod Pathol*. 2010 Jun;23(6):781-9.
9. Brierley JD, Gospodarowicz MK, Wittekind C, editors. *TNM classification of malignant tumours*. 8th ed. Oxford, UK: Wiley-Blackwell; 2017.
10. Seidman JD, Ronnett BM, Shih I-M, Cho KR, Kurman RJ. Epithelial Tumors of the Ovary. In: RJ Kurman, LH Ellenson, Ronnett B, editors. *Blaustein's Pathology of the Female Genital Tract*. 7 ed. Switzerland: Springer; 2019. p. 841-966.
11. Ramalingam P, Masand RP, Euscher ED, et al. Undifferentiated carcinoma of the endometrium: an expanded immunohistochemical analysis including PAX-8 and basal-like carcinoma surrogate markers. *Int J Gynecol Pathol*. 2016 Sep;35(5):410-8.
12. McCluggage WG, Oliva E, Connolly LE, et al. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type. *Int J Gynecol Pathol*. 2004 Oct;23(4):330-6.
13. Taraif SH, Deavers MT, Malpica A, et al. The significance of neuroendocrine expression in undifferentiated carcinoma of the endometrium. *Int J Gynecol Pathol*. 2009 Mar;28(2):142-7.

14. Kunkel J, Peng Y, Tao Y, et al. Presence of a sarcomatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/Mullerian tumors: a clinicopathologic study of 47 cases. *Am J Surg Pathol*. 2012 Jun;36(6):831-7.
15. Ali-Fehmi R, Carlson JW, Matias-Guiu X. Carcinosarcoma of the ovary. In: Cheung AN, Ellenson LH, Gilks CB, Kim K-R KC, Lax SF, Longacre TA, et al., editors. *Female Genital Tumours, WHO Classification of Tumours*. 5 ed. France: International Agency for Research on Cancer (IARC); 2020. p. 81.
16. Clement PB, Stall JN, Young RH. *Atlas of Gynecologic Surgical Pathology*, Fourth edition; 2020.
17. Fujii H, Yoshida M, Gong ZX, et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. *Cancer Res*. 2000 Jan 1;60(1):114-20.
18. Gallardo A, Matias-Guiu X, Lagarda H, et al. Malignant Mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases. *Int J Gynecol Pathol*. 2002 Jul;21(3):268-72.
19. Ladwig NR, Schoolmeester JK, Weil L, et al. Inflammatory myofibroblastic tumor associated with the placenta: short tandem repeat genotyping confirms uterine site of origin. *Am J Surg Pathol*. 2018 Jun;42(6):807-12.
20. Harmankaya İ. Uterin Karsinosarkomların Literatür Eşliğinde Değerlendirilmesi. *Int J Acad Med Pharm*. 2020; 2(2); 152-157.
21. Zhao S, Bellone S, Lopez S, et al. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial- mesenchymal transition. *Proc Natl Acad Sci U S A*. 2016 Oct 25;113(43):12238-43.
22. Kobel M, Malpica A. Mixed carcinoma of the ovary. In: Cheung AN, Ellenson LH, Gilks CB, Kim K-R KC, Lax SF, Longacre TA, et al., editors. *Female Genital Tumours, WHO Classification of Tumours*. 5 ed. France: International Agency for Research on Cancer (IARC); 2020. p. 83.
23. Mackenzie R, Talhouk A, Eshragh S, et al. Morphologic and molecular characteristics of mixed epithelial ovarian cancers. *Am J Surg Pathol*. 2015 Nov;39(11):1548-57.
24. Kobel M, Rahimi K, Rambau PF, et al. An immunohistochemical algorithm for ovarian carcinoma typing. *Int J Gynecol Pathol*. 2016 Sep;35(5):430-41.